Back
ESC Premium Access

Rivaroxaban prevents the development of chronic thromboembolic pulmonary hypertension in mice- Novel beneficial effects of the FXa inhibitor-

Session: What is new in venous thromboembolism?
Topic: Treatment of hypertension
Speaker: Mr M. Al-Mamun (Sendai, JP)
Event: ESC Congress 2017

Congress Presentation

About the speaker

Mr Md Elias Al-Mamun

Tohoku University Graduate School of Medicine, Sendai (Japan)
0 follower

6 more presentations in this session

Long-term effects of unprovoked venous thromboembolism on mortality and major cardiovascular events

Speaker: Doctor W. Chang (Tainan, TW)

Access
Abstract
Slides
Thumbnail

Comparative safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism - a Danish nationwide study

Speaker: Ms C. Sindet-Pedersen (Hellerup, DK)

Access
Abstract
Thumbnail

Validation of the prognostic impact of copeptin in normotensive pulmonary embolism in a european multicentre study.

Speaker: Doctor K. Hellenkamp (Goettingen, DE)

Access
Abstract
Slides
Thumbnail

A novel experimental in vivo model of acute pulmonary embolism

Speaker: Doctor J. Schultz (Aarhus, DK)

Access
Abstract
Slides
Thumbnail

The YEARS algorithm for suspected pulmonary embolism leads to much shorter diagnostic turnaround time than conventional algorithms

Speaker: Doctor E. Klok (Leiden, NL)

Access
Abstract
Slides
Thumbnail

Access the full session

What is new in venous thromboembolism?

Speakers: Mr M. Al-Mamun, Doctor W. Chang, Ms C. Sindet-Pedersen, Doctor K. Hellenkamp, Doctor J. Schultz...
Access
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb